Post-rituximab Burkitt transformation of PTLD: loss of CD20 expression accompanied by a switch in light-chain expression

Ann Hematol. 2010 Jan;89(1):97-9. doi: 10.1007/s00277-009-0769-8. Epub 2009 Jun 9.

Authors

Yu-Yan Hwang, Kai Y Wong, Rock Y Y Leung, Simon H M Wong, See-Ching Chan, Gopesh Srivastava, Wing Y Au

PMID: 19506869
DOI: 10.1007/s00277-009-0769-8

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Antibodies, Monoclonal, Murine-Derived / therapeutic use*
Antigens, CD20 / genetics
Antigens, CD20 / metabolism*
Base Sequence
Burkitt Lymphoma / drug therapy*
Burkitt Lymphoma / genetics
Burkitt Lymphoma / pathology
Cell Transformation, Neoplastic / genetics
Cell Transformation, Neoplastic / pathology*
Fatal Outcome
Female
Gene Expression Regulation, Neoplastic
Humans
Immunoglobulin Light Chains / biosynthesis
Immunoglobulin Light Chains / genetics
Liver Transplantation* / pathology
Lymphoproliferative Disorders / drug therapy*
Lymphoproliferative Disorders / genetics
Lymphoproliferative Disorders / pathology
Middle Aged
Molecular Sequence Data
Rituximab

Substances

Antibodies, Monoclonal, Murine-Derived
Antigens, CD20
Immunoglobulin Light Chains
Rituximab